Muncy Columbia Financial 3Q 2026: Revenue $18.24M, EPS $0.57 — 10-Q Summary

Muncy Columbia Financial reported 3Q 2026 revenue of $18.24M and EPS of $0.57, with net interest income up 12.7% to $17.6M. Earnings declined year-over-year due to $2.4M in losses on debt securities. Net interest margin increased 39 basis points to 4.54%, and loans rose 2.6% to $1.208B.

Original reporting
Published Nov 6, 2026, 4:31 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 6, 2026, 4:38 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Muncy Columbia Financial 3Q 2026: Revenue $18.24M, EPS $0.57 — 10-Q Summary — source image
Decision brief

The 30-second read

$CCFNBearishLow
01

Why it matters

The disclosed loss reduces quarterly EPS to $0.57, potentially prompting short‑term price weakness.

02

Market read

Earnings recap with modest negative surprise; limited trading relevance.

03

What to watch

Higher net interest margin and loan growth could support future earnings.

Relevance 4/10Novelty 2/10Timing: post‑release recap

Background

Muncy Columbia Financial released its 3Q 2026 10‑Q, highlighting net interest income growth but a drop in earnings due to securities losses.

Company-level read

Ticker impact

$CCFNBearishMedium confidence
Context

The 10‑Q filing shows $2.4M realized losses on available‑for‑sale securities, reducing earnings YoY.

Expected impact

likely downward pressure as the market prices in the loss

Evidence & confidence

Realized losses are a fresh negative earnings component, but the scale is modest for a micro‑cap.

Market effects

Minimal impact on the regional banking sector; loss is company‑specific.

Negligible effect on broader market.

None

Counterpoint

The loss may be temporary; higher net interest income could offset concerns.

Key entities

  • Muncy Columbia Financial Corp

    Regional bank reporting Q3 2026 results.

Related articles

$CCFNMed

Muncy Columbia Financial Corporation Announces Third Quarter 2026 Earnings

MUNCY COLUMBIA FINANCIAL Corp (CCFN) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Press Release – For Immediate Release October 19, 2026 Muncy Columbia Financial Corporation Announces Third Quarter 2026 Earnings Bloomsburg, PA – Muncy Columbia Financial Corporation (“Corporation”) (OTCQX: CCFN), parent company of Journey Bank (“Bank”), has release

$CCFNMed

Muncy Columbia Financial Corporation Announces Second Quarter 2026 Earnings

MUNCY COLUMBIA FINANCIAL Corp (CCFN) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 ex99-1.htm EX-99.1 Exhibit 99.1 Press Release – For Immediate Release July 20, 2026 Muncy Columbia Financial Corporation Announces Second Quarter 2026 Earnings Bloomsburg, PA – Muncy Columbia Financial Corporation (“Corporation”) (OTCQX: CCFN), parent company of Journey

$MRCYMed

Mercury Systems 3Q 2026: Revenue $253.15M, EPS $0.21 — 10-Q Summary

Mercury Systems reported 3Q 2026 revenue of $253.15M, up 12.4% YoY, and net income of $13.09M, reversing a prior-year loss. Growth in radar and electronic warfare applications drove results, while C4I revenue declined. Gross margin improved to 35.2% from 27.9%. The company expects to recognize 46% of its $1.193B remaining performance obligations as revenue in the next 12 months.

$SNWVMed

Sanuwave Announces Q3 FY2026 Financial Results

SANUWAVE Health, Inc. (SNWV) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Sanuwave Announces Q3 FY2026 Financial Results Q3 2026 revenues were $8.6 million, down 24% from $11.3 million in Q3 2025. Q3 2026 gross margin was 77.3%, versus 77.6% in Q3 2025. GAAP operating loss was $1.1 million for Q3 2026 versus operating income of $0.9 millio

$CPIXHighAI 8/10

CUMBERLAND PHARMACEUTICALS REPORTS Q3 2026 FINANCIAL RESULTS & COMPANY UPDATE

CUMBERLAND PHARMACEUTICALS INC (CPIX) filed an SEC Form 8-K — Results of Operations and Financial Condition. CUMBERLAND PHARMACEUTICALS REPORTS Q3 2026 FINANCIAL RESULTS & COMPANY UPDATE $100 million Strategic Transaction Closed Plans to Submit New Drug Application for Ifetroban in DMD Top-Line Results Announced for Systemic Sclerosis Trial NASHVILLE, Tenn. (Nov. 10, 2026) – Cumberland

$ATROHighAI 8/10

Astronics shares tumble on soft fourth quarter revenue outlook

Astronics (ATRO) reported Q3 earnings of $1.08 per share, beating estimates, with revenue up 28.5% YoY to $271.7M. However, shares fell 11% on Q4 revenue guidance of $255M-$275M, below expectations. The company maintained its full-year 2026 revenue guidance. Aerospace segment sales hit a record $245.5M, with strong demand in inflight entertainment and connectivity.